ibi302
mAbexperimentalMulti-specific
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Apr 16, 2019 (NCT03814291)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Complement C5INHIBITOR
C5 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07275840 | Phase 2 | Dec 9, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06908876 | Phase 2 | Apr 24, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05972473 | Phase 3 | Aug 15, 2023 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05403749 | Phase 2 | Jun 15, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05961007 | Phase 1/Phase 2 (Phase 2) | Nov 18, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04820452 | Phase 2 | May 1, 2021 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT04370379 | Phase 1 | May 31, 2020 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT03814291 | Phase 1 | Apr 16, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 8 | 8 | 3 | 2019 |
1 organizations
Page 1 / 1